Treatment progress of diffuse large B-cell lymphoma: reports from the 57th American Society of Hematology annual meeting

VernacularTitle:弥漫大B细胞淋巴瘤治疗进展:第57届美国血液学会年会报道
Author: Tingxun LU ; Dong HUA ; Wei XU ; Jianyong LI
Publication Type:Journal Article
Keywords: Lymphoma; large B-cell; diffuse; Therapy; American Society of Hematology annual meeting
From: Journal of Leukemia & Lymphoma 2016;25(1):19-22
CountryChina
Language:Chinese
Abstract: Diffuse large B-cell lymphoma (DLBCL) is one of the most common non-Hodgkin lymphomaaccounting for 30 %-40 %. The most common first-line therapy for DLBCL is rituximab in combination withchemotherapy. About two thirds of patients treated by the first-line therapy achieve a complete remission (CR)and are cured finally, but nearly one third of patients can not reach CR after frontline treatment appearingrefractory or relapse early, especially for the high risk patients or cases with MYC alterations, the regimenimproving the long-term survival is not much. In the 57th American Society of Hematology (ASH) annualmeeting, a plenty of treatment as focus on these patients brought in encouraging results, which makes itpossible to further improve the CR rate. The progresses on DLBCL of relapse and refractory, high risk andspecial types were summarized in this paper based on the reports in the 57th ASH annual meeting.